Overall impact
C (51)

Commentary

Fresenius is an average overall performer. With a 'C' rating of 51.1 for overall impact (43rd percentile compared to all companies), Fresenius ranks 11th out of 13 industry peers, behind Abbott, Smith & Nephew, Getinge and 7 others, and ahead of Stryker and Zimmer Biomet. On top material causes for Fresenius's industry (Healthcare Equipment), Fresenius performs well in Decent, Safe Work Opportunities (95.1 score), Sanitation Access (95.4), Disaster Readiness and Effective Aid (84.9) and 2 other causes where it received an 'A' score and performs poorly in Accountable Institutions (38.2 score), Disease Eradication (0.0), Racial Justice and Civil Rights (25.4) and 5 other causes where it received a 'D' or 'F' score.
Impact
Cause FMS
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
111,513
Sector
Financials
Industry
Banks
Sub-industry
Diversified Banks
SASB industry
Health Care Delivery
Headquarters
Germany
Share classes
FSNUY
ADR
FMS
Description
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Material causes
Ethos considers the following causes material for Fresenius, based on its industry sub-industry Diversified Banks. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.